Welcome to this UK AstraZeneca produced and funded website
This website is intended for UK Healthcare Professionals only.
The website contains both promotional and non-promotional content.
If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk
For any other UK residents please visit astrazeneca.co.uk
This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk
Therapeutic Indication: IMFINZI (durvalumab) in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of eligible adults with resectable gastric and gastro-oesophageal junction adenocarcinoma1
Always refer to the Summary of Product Characterictics before prescribing
*The MATTERHORN trial was a global double-blind Phase III trial, whereby eligible patients with resectable GC/GOJC were assigned in a 1:1 ratio to receive IMFINZI 1500 mg (N=474) or placebo Q4W on Day 1 of each cycle, plus FLOT chemotherapy, Q2W on Day 1 and Day 15 of each cycle for 4 cycles (N=474; 2 cycles of each neoadjuvant and adjuvant therapy), followed by IMFINZI 1500 mg or placebo Q4W for 10 cycles.3
Patients treated with perioperative IMFINZI + FLOT achieved statistically significant and clinically meaningful event-free survival (primary endpoint) and met key secondary endpoints; two-year EFS was 67.4% vs. 58.5% in the IMFINZI group vs. the FLOT alone group (HR for event or death, 0.71 [95% CI 0.58–0.86]; p<0.001)3–5
The safety profile for the combination of IMFINZI + FLOT was consistent with the known profiles of each agent3,4
The addition of IMFINZI to FLOT saw double the pathological complete response rates (key secondary endpoint) with no impact to surgical completion vs. FLOT alone, with 19.2% observed in the IMFINZI group vs. 7.2% in the FLOT alone (RR, 2.69 [95% CI 1.86-3.90]3,4
GB-77157 | August 2026
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.
GB-74216| DOP : February 2026
